ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Novavax, Inc." (NVAX) Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Novavax, Inc." (NVAX)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: ANAC, ATNM, INSY, BCRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Novavax, Inc."© quotemedia

Company Profile

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particles (VLP) and recombinant nanoparticle vaccine technology. It is developing vaccine product candidates to protect against various circulating strains of pandemic influenza, including H1N1 and H5N1 influenza, as well as seasonal flu and respiratory syncytial virus (RSV). The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and manufacture the company’s pandemic and seasonal influenza vaccine candidates, Cadila’s biogeneric products, and other diagnostic products for the territory of India; and a licensing agreement with LG Life Sciences, Ltd. to use the company’s VLP technology to develop and sell the company’s influenza vaccines in South Korea and other countries. It also has a joint venture with CPL Biologics Private Limited for developing a rabies vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.

Recent News: "Novavax, Inc."